Literature DB >> 18511598

Hypermethylation of CXCR4 promoter in CD34+ cells from patients with primary myelofibrosis.

Costanza Bogani1, Vanessa Ponziani, Paola Guglielmelli, Cristophe Desterke, Vittorio Rosti, Alberto Bosi, Marie-Caroline Le Bousse-Kerdilès, Giovanni Barosi, Alessandro M Vannucchi.   

Abstract

Constitutive mobilization of CD34(+) cells in patients with primary myelofibrosis (PMF) has been attributed to proteolytic disruption of the CXCR4/SDF-1 axis and reduced CXCR4 expression. We document here that the number of circulating CD34(+)/CXCR4(+) cells in PMF patients, as well as the cellular CXCR4 expression, was directly related to CXCR4 mRNA level and that reduced CXCR4 mRNA level was not due to SDF-1-induced downregulation. To address whether epigenetic regulation contributes to defective CXCR4 expression, we studied the methylation status of the CXCR4 promoter using methylation-specific polymerase chain reaction and methylation-specific sequencing in the JAK2V617F-positive HEL cell line and in CD34(+) cells. We found that CD34(+) cells from PMF patients, unlike those from normal subjects, presented hypermethylation of CXCR4 promoter CpG island 1. Following incubation with the demethylating agent 5-Aza-2'-deoxycytidine (5-AzaD), the percentage of PMF CD34(+) cells expressing CXCR4 increased 3-10 times, whereas CXCR4 mRNA level increased approximately 4 times. 5-AzaD-treated PMF CD34(+) cells displayed almost complete reversal of CpG1 island 1 hypermethylation and showed enhanced migration in vitro in response to SDF-1. These data point to abnormal methylation of the CXCR4 promoter as a mechanism contributing to constitutive migration of CD34(+) cells in PMF. Disclosure of potential conflicts of interest is found at the end of this article.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18511598     DOI: 10.1634/stemcells.2008-0377

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  40 in total

1.  CXCR4-independent rescue of the myeloproliferative defect of the Gata1low myelofibrosis mouse model by Aplidin.

Authors:  Maria Verrucci; Alessandro Pancrazzi; Miguel Aracil; Fabrizio Martelli; Paola Guglielmelli; Maria Zingariello; Barbara Ghinassi; Emanuela D'Amore; José Jimeno; Alessandro M Vannucchi; Anna Rita Migliaccio
Journal:  J Cell Physiol       Date:  2010-11       Impact factor: 6.384

2.  CD133 marks a stem cell population that drives human primary myelofibrosis.

Authors:  Ioanna Triviai; Thomas Stübig; Birte Niebuhr; Kais Hussein; Asterios Tsiftsoglou; Boris Fehse; Carol Stocking; Nicolaus Kröger
Journal:  Haematologica       Date:  2015-02-27       Impact factor: 9.941

Review 3.  Allo-SCT for myelofibrosis: reversing the chronic phase in the JAK inhibitor era?

Authors:  R Tamari; T I Mughal; D Rondelli; R Hasserjian; V Gupta; O Odenike; V Fauble; G Finazzi; F Pane; J Mascarenhas; J Prchal; S Giralt; R Hoffman
Journal:  Bone Marrow Transplant       Date:  2015-02-09       Impact factor: 5.483

Review 4.  Preclinical models for drug selection in myeloproliferative neoplasms.

Authors:  Niccolò Bartalucci; Costanza Bogani; Alessandro M Vannucchi
Journal:  Curr Hematol Malig Rep       Date:  2013-12       Impact factor: 3.952

Review 5.  Bone marrow fibrosis in primary myelofibrosis: pathogenic mechanisms and the role of TGF-β.

Authors:  Archana Agarwal; Kerry Morrone; Matthias Bartenstein; Zhizhuang Joe Zhao; Amit Verma; Swati Goel
Journal:  Stem Cell Investig       Date:  2016-02-26

6.  Correction of the abnormal trafficking of primary myelofibrosis CD34+ cells by treatment with chromatin-modifying agents.

Authors:  Xiaoli Wang; Wei Zhang; Takefumi Ishii; Selcuk Sozer; Jiapeng Wang; Mingjiang Xu; Ronald Hoffman
Journal:  Cancer Res       Date:  2009-09-14       Impact factor: 12.701

7.  A3669G polymorphism of glucocorticoid receptor is a susceptibility allele for primary myelofibrosis and contributes to phenotypic diversity and blast transformation.

Authors:  Valentina Poletto; Vittorio Rosti; Laura Villani; Paolo Catarsi; Adriana Carolei; Rita Campanelli; Margherita Massa; Myriam Martinetti; Gianluca Viarengo; Alberto Malovini; Anna Rita Migliaccio; Giovanni Barosi
Journal:  Blood       Date:  2012-08-09       Impact factor: 22.113

8.  Tetraspanin CD9 participates in dysmegakaryopoiesis and stromal interactions in primary myelofibrosis.

Authors:  Christophe Desterke; Christophe Martinaud; Bernadette Guerton; Lisa Pieri; Costanza Bogani; Denis Clay; Frederic Torossian; Jean-Jacques Lataillade; Hans C Hasselbach; Heinz Gisslinger; Jean-Loup Demory; Brigitte Dupriez; Claude Boucheix; Eric Rubinstein; Sophie Amsellem; Alessandro M Vannucchi; Marie-Caroline Le Bousse-Kerdilès
Journal:  Haematologica       Date:  2015-04-03       Impact factor: 9.941

Review 9.  Advances in myelofibrosis: a clinical case approach.

Authors:  John O Mascarenhas; Attilio Orazi; Kapil N Bhalla; Richard E Champlin; Claire Harrison; Ronald Hoffman
Journal:  Haematologica       Date:  2013-10       Impact factor: 9.941

10.  Methylome profiling reveals distinct alterations in phenotypic and mutational subgroups of myeloproliferative neoplasms.

Authors:  Sangeeta Nischal; Sanchari Bhattacharyya; Maximilian Christopeit; Yiting Yu; Li Zhou; Tushar D Bhagat; Davendra Sohal; Britta Will; Yongkai Mo; Masako Suzuki; Animesh Pardanani; Michael McDevitt; Jaroslaw P Maciejewski; Ari M Melnick; John M Greally; Ulrich Steidl; Alison Moliterno; Amit Verma
Journal:  Cancer Res       Date:  2012-10-11       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.